BioLife Solutions (BLFS) Stock Forecast, Price Target & Predictions
BLFS Stock Forecast
BioLife Solutions stock forecast is as follows: an average price target of $26.00 (represents a 1.72% upside from BLFS’s last price of $25.56) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
BLFS Price Target
The average price target for BioLife Solutions (BLFS) is $26.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $22.00. This represents a potential 1.72% upside from BLFS's last price of $25.56.
BLFS Analyst Ratings
According to 6 Wall Street analysts, BioLife Solutions's rating consensus is 'Buy'. The analyst rating breakdown for BLFS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioLife Solutions Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 12, 2024 | Matt Hewitt | Craig-Hallum | $30.00 | $25.25 | 18.81% | 17.37% |
| Apr 04, 2024 | Matthew Stanton | Jefferies | $22.00 | $17.32 | 27.02% | -13.93% |
The latest BioLife Solutions stock forecast, released on Aug 12, 2024 by Matt Hewitt from Craig-Hallum, set a price target of $30.00, which represents a 18.81% increase from the stock price at the time of the forecast ($25.25), and a 17.37% increase from BLFS last price ($25.56).
BioLife Solutions Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $30.00 | $26.00 |
| Last Closing Price | $25.56 | $25.56 | $25.56 |
| Upside/Downside | -100.00% | 17.37% | 1.72% |
In the current month, the average price target of BioLife Solutions stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioLife Solutions's last price of $25.56. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 30, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Aug 12, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jul 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 13, 2024 | Benchmark | - | Buy | Upgrade |
| Apr 04, 2024 | Jefferies | - | Buy | Initialise |
| Apr 25, 2022 | Oppenheimer | - | Outperform | Upgrade |
BioLife Solutions's last stock rating was published by H.C. Wainwright on Sep 30, 2024. The company Initialise its BLFS rating from "null" to "Buy".
BioLife Solutions Financial Forecast
BioLife Solutions Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $32.73M | $33.33M | $39.51M | $37.70M | $44.26M | $40.75M | $40.53M | $36.22M | $37.30M | $33.80M | $31.20M | $16.85M | $14.73M | $11.28M | $9.92M | $12.16M | $8.30M | $6.60M |
| Avg Forecast | $36.95M | $35.56M | $35.06M | $32.68M | $32.20M | $31.06M | $29.72M | $28.03M | $26.08M | $25.54M | $23.95M | $26.01M | $33.40M | $33.01M | $43.63M | $42.94M | $43.40M | $42.06M | $39.17M | $38.21M | $35.81M | $31.59M | $27.58M | $16.05M | $13.54M | $10.78M | $9.57M | $11.15M | $9.01M | $7.63M |
| High Forecast | $36.95M | $35.56M | $35.06M | $32.68M | $32.20M | $31.06M | $29.72M | $28.03M | $26.08M | $26.09M | $23.95M | $26.01M | $33.40M | $33.01M | $43.63M | $42.94M | $43.40M | $42.06M | $39.17M | $38.21M | $35.81M | $31.59M | $27.58M | $16.05M | $13.54M | $10.78M | $9.57M | $11.15M | $9.01M | $7.63M |
| Low Forecast | $36.95M | $35.56M | $35.06M | $32.68M | $32.20M | $31.06M | $29.72M | $28.03M | $26.08M | $24.46M | $23.95M | $26.01M | $33.40M | $33.01M | $43.63M | $42.94M | $43.40M | $42.06M | $39.17M | $38.21M | $35.81M | $31.59M | $27.58M | $16.05M | $13.54M | $10.78M | $9.57M | $11.15M | $9.01M | $7.63M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.01% | 0.91% | 0.88% | 1.02% | 0.97% | 1.03% | 0.95% | 1.04% | 1.07% | 1.13% | 1.05% | 1.09% | 1.05% | 1.04% | 1.09% | 0.92% | 0.87% |
BioLife Solutions's average Quarter revenue forecast for Mar 24 based on 2 analysts is $26.01M, with a low forecast of $26.01M, and a high forecast of $26.01M. BLFS's average Quarter revenue forecast represents a -20.55% decrease compared to the company's last Quarter revenue of $32.73M (Dec 23).
BioLife Solutions EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-13.15M | $-11.36M | $-15.28M | $-11.03M | $-8.32M | $-3.10M | $-4.27M | $-9.77M | $-9.14M | $-13.54M | $2.42M | $1.86M | $-2.61M | $129.00K | $-122.00K | $1.66M | $454.00K | $38.00K |
| Avg Forecast | $-5.35M | $-5.15M | $-5.08M | $-4.73M | $-4.66M | $-4.50M | $-4.30M | $-4.06M | $-3.78M | $-3.70M | $-3.47M | $-4.50M | $-4.84M | $-4.78M | $-6.32M | $-4.81M | $-11.63M | $-6.09M | $-5.67M | $-4.37M | $-5.19M | $-4.58M | $-3.99M | $740.00K | $-1.96M | $-1.56M | $-1.39M | $-1.61M | $-1.31M | $-1.10M |
| High Forecast | $-5.35M | $-5.15M | $-5.08M | $-4.73M | $-4.66M | $-4.50M | $-4.30M | $-4.06M | $-3.78M | $-3.54M | $-3.47M | $-3.60M | $-4.84M | $-4.78M | $-6.32M | $-3.85M | $-9.30M | $-6.09M | $-5.67M | $-3.50M | $-5.19M | $-4.58M | $-3.99M | $888.00K | $-1.96M | $-1.56M | $-1.39M | $-1.61M | $-1.31M | $-1.10M |
| Low Forecast | $-5.35M | $-5.15M | $-5.08M | $-4.73M | $-4.66M | $-4.50M | $-4.30M | $-4.06M | $-3.78M | $-3.78M | $-3.47M | $-5.40M | $-4.84M | $-4.78M | $-6.32M | $-5.77M | $-13.96M | $-6.09M | $-5.67M | $-5.25M | $-5.19M | $-4.58M | $-3.99M | $592.00K | $-1.96M | $-1.56M | $-1.39M | $-1.61M | $-1.31M | $-1.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.72% | 2.38% | 2.42% | 2.29% | 0.72% | 0.51% | 0.75% | 2.23% | 1.76% | 2.96% | -0.61% | 2.52% | 1.33% | -0.08% | 0.09% | -1.03% | -0.35% | -0.03% |
2 analysts predict BLFS's average Quarter EBITDA for Sep 21 to be $-4.58M, with a high of $-4.58M and a low of $-4.58M. This is -288.70% lower than BioLife Solutions's previous annual EBITDA (Jun 21) of $2.42M.
BioLife Solutions Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-13.47M | $-29.13M | $-10.20M | $-13.71M | $-49.19M | $-9.96M | $-72.55M | $-7.07M | $-14.47M | $79.00K | $7.88M | $-1.12M | $-2.13M | $-1.13M | $-16.38M | $22.31M | $-12.24M | $9.32M |
| Avg Forecast | $1.84M | $920.08K | $920.08K | $460.04K | $-2.30M | $-2.53M | $-2.53M | $-2.99M | $-3.37M | $-3.60M | $-6.36M | $-9.59M | $-15.72M | $-17.25M | $-9.66M | $-10.26M | $-13.29M | $-7.59M | $-9.61M | $-9.33M | $-7.75M | $-3.94M | $-1.90M | $-1.40M | $-747.57K | $-722.91K | $-1.51M | $1.10B | $-817.86K | $1.07M |
| High Forecast | $1.84M | $920.08K | $920.08K | $460.04K | $-2.30M | $-2.53M | $-2.53M | $-2.99M | $-3.37M | $-2.00M | $-6.36M | $-7.67M | $-15.72M | $-17.25M | $-9.66M | $-8.21M | $-10.64M | $-7.59M | $-9.61M | $-7.46M | $-7.75M | $-3.94M | $-1.90M | $-1.12M | $-747.57K | $-722.91K | $-1.51M | $1.33B | $-817.86K | $1.07M |
| Low Forecast | $1.84M | $920.08K | $920.08K | $460.04K | $-2.30M | $-2.53M | $-2.53M | $-2.99M | $-3.37M | $-4.80M | $-6.36M | $-11.51M | $-15.72M | $-17.25M | $-9.66M | $-12.31M | $-15.95M | $-7.59M | $-9.61M | $-11.19M | $-7.75M | $-3.94M | $-1.90M | $-1.68M | $-747.57K | $-722.91K | $-1.51M | $883.40M | $-817.86K | $1.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.86% | 1.69% | 1.06% | 1.34% | 3.70% | 1.31% | 7.55% | 0.76% | 1.87% | -0.02% | -4.15% | 0.80% | 2.85% | 1.57% | 10.84% | 0.02% | 14.96% | 8.68% |
BioLife Solutions's average Quarter net income forecast for Dec 21 is $-7.75M, with a range of $-7.75M to $-7.75M. BLFS's average Quarter net income forecast represents a -9916.33% decrease compared to the company's last Quarter net income of $79.00K (Sep 21).
BioLife Solutions SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $17.51M | $19.77M | $21.72M | $21.31M | $18.56M | $16.86M | $16.77M | $16.09M | $15.17M | $14.15M | $10.29M | $6.85M | $6.57M | $5.09M | $4.64M | $4.71M | $3.98M | $3.52M |
| Avg Forecast | $17.31M | $16.66M | $16.43M | $15.31M | $15.09M | $14.55M | $13.92M | $13.13M | $12.22M | $11.97M | $11.22M | $21.84M | $15.65M | $15.47M | $20.45M | $23.36M | $13.93M | $19.71M | $18.35M | $21.23M | $16.78M | $14.80M | $12.92M | $8.56M | $6.35M | $5.05M | $4.48M | $5.22M | $4.22M | $3.57M |
| High Forecast | $17.31M | $16.66M | $16.43M | $15.31M | $15.09M | $14.55M | $13.92M | $13.13M | $12.22M | $12.22M | $11.22M | $26.21M | $15.65M | $15.47M | $20.45M | $28.03M | $16.72M | $19.71M | $18.35M | $25.48M | $16.78M | $14.80M | $12.92M | $10.28M | $6.35M | $5.05M | $4.48M | $5.22M | $4.22M | $3.57M |
| Low Forecast | $17.31M | $16.66M | $16.43M | $15.31M | $15.09M | $14.55M | $13.92M | $13.13M | $12.22M | $11.46M | $11.22M | $17.47M | $15.65M | $15.47M | $20.45M | $18.69M | $11.15M | $19.71M | $18.35M | $16.99M | $16.78M | $14.80M | $12.92M | $6.85M | $6.35M | $5.05M | $4.48M | $5.22M | $4.22M | $3.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | 1.28% | 1.06% | 0.91% | 1.33% | 0.86% | 0.91% | 0.76% | 0.90% | 0.96% | 0.80% | 0.80% | 1.04% | 1.01% | 1.04% | 0.90% | 0.94% | 0.98% |
BioLife Solutions's average Quarter SG&A projection for Mar 24 is $21.84M, based on 2 Wall Street analysts, with a range of $17.47M to $26.21M. The forecast indicates a 24.75% rise compared to BLFS last annual SG&A of $17.51M (Dec 23).
BioLife Solutions EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 15 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.67 | $-0.00 | $-0.32 | $-1.15 | $-0.23 | $-1.71 | $-0.17 | $-0.35 | - | $0.20 | $-0.07 | $-0.06 | $-0.04 | $-1.35 | $2.10 | $-0.59 | $0.97 |
| Avg Forecast | $0.04 | $0.02 | $0.02 | $0.01 | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.08 | $-0.14 | $-0.31 | $-0.34 | $-0.38 | $-0.21 | $-0.21 | $-0.16 | $-0.17 | $-0.21 | $-0.26 | $-0.17 | $-0.09 | $-0.04 | $-0.04 | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $0.02 |
| High Forecast | $0.04 | $0.02 | $0.02 | $0.01 | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.04 | $-0.14 | $-0.31 | $-0.34 | $-0.38 | $-0.21 | $-0.21 | $-0.16 | $-0.17 | $-0.21 | $-0.26 | $-0.17 | $-0.09 | $-0.04 | $-0.04 | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $0.02 |
| Low Forecast | $0.04 | $0.02 | $0.02 | $0.01 | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.10 | $-0.14 | $-0.31 | $-0.34 | $-0.38 | $-0.21 | $-0.21 | $-0.16 | $-0.17 | $-0.21 | $-0.26 | $-0.17 | $-0.09 | $-0.04 | $-0.04 | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $0.02 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 1.79% | 0.00% | 1.50% | 7.13% | 1.39% | 8.19% | 0.65% | 2.08% | -0.02% | -4.85% | 1.89% | 3.98% | 2.42% | 41.09% | -76.36% | 33.19% | 41.57% |
According to 2 Wall Street analysts, BioLife Solutions's projected average Quarter EPS for Dec 21 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.17. This represents a -8972.11% decrease compared to BLFS previous annual EPS of - (Sep 21).
BioLife Solutions Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NSTG | NanoString | $0.11 | $21.50 | 19445.45% | Buy |
| AKYA | Akoya Biosciences | $2.62 | $7.90 | 201.53% | Buy |
| COO | Cooper Companies | $104.86 | $298.00 | 184.19% | Buy |
| ANGO | AngioDynamics | $6.74 | $15.00 | 122.55% | Buy |
| ATRC | AtriCure | $33.66 | $49.57 | 47.27% | Buy |
| TFX | Teleflex | $207.33 | $304.82 | 47.02% | Buy |
| HAE | Haemonetics | $73.53 | $104.33 | 41.89% | Buy |
| KRMD | KORU Medical Systems | $2.68 | $3.75 | 39.93% | Buy |
| WST | West Pharmaceutical Services | $314.77 | $345.33 | 9.71% | Buy |
| ALC | Alcon | $92.17 | $93.89 | 1.87% | Buy |
| BLFS | BioLife Solutions | $25.56 | $26.00 | 1.72% | Buy |
| ICUI | ICU Medical | $172.00 | $172.00 | - | Buy |
| RMD | ResMed | $243.61 | $219.13 | -10.05% | Hold |
| ATR | AptarGroup | $168.26 | $138.00 | -17.98% | Buy |
BLFS Forecast FAQ
Is BioLife Solutions a good buy?
Yes, according to 6 Wall Street analysts, BioLife Solutions (BLFS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of BLFS's total ratings.
What is BLFS's price target?
BioLife Solutions (BLFS) average price target is $26 with a range of $22 to $30, implying a 1.72% from its last price of $25.56. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BioLife Solutions stock go up soon?
According to Wall Street analysts' prediction for BLFS stock, the company can go up by 1.72% (from the last price of $25.56 to the average price target of $26), up by 17.37% based on the highest stock price target, and down by -13.93% based on the lowest stock price target.
Can BioLife Solutions stock reach $40?
BLFS's average twelve months analyst stock price target of $26 does not support the claim that BioLife Solutions can reach $40 in the near future.
What are BioLife Solutions's analysts' financial forecasts?
BioLife Solutions's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $121M (high $121M, low $121M), average EBITDA is $-17.527M (high $-17.527M, low $-17.527M), average net income is $-10.351M (high $-10.351M, low $-10.351M), average SG&A $56.69M (high $56.69M, low $56.69M), and average EPS is $-0.225 (high $-0.225, low $-0.225). BLFS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $140.25M (high $140.25M, low $140.25M), average EBITDA is $-20.315M (high $-20.315M, low $-20.315M), average net income is $4.14M (high $4.14M, low $4.14M), average SG&A $65.72M (high $65.72M, low $65.72M), and average EPS is $0.09 (high $0.09, low $0.09).
Did the BLFS's actual financial results beat the analysts' financial forecasts?
Based on BioLife Solutions's last annual report (Dec 2023), the company's revenue was $143.27M, which missed the average analysts forecast of $152.99M by -6.35%. Apple's EBITDA was $-70.825M, beating the average prediction of $-20.749M by 241.35%. The company's net income was $-66.089M, beating the average estimation of $-52.89M by 24.95%. Apple's SG&A was $80.31M, beating the average forecast of $74.92M by 7.19%. Lastly, the company's EPS was $-0.0015, missing the average prediction of $-1.14 by -99.87%. In terms of the last quarterly report (Dec 2023), BioLife Solutions's revenue was $32.73M, missing the average analysts' forecast of $33.4M by -2.00%. The company's EBITDA was $-13.155M, beating the average prediction of $-4.838M by 171.92%. BioLife Solutions's net income was $-13.469M, missing the average estimation of $-15.718M by -14.31%. The company's SG&A was $17.51M, beating the average forecast of $15.65M by 11.87%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.342 by -99.91%